April 11, 2024 06:59 AM EDTUpdated 01:18 PM
Pharma
Law

US sues Re­gen­eron over ‘hun­dreds of mil­lions’ in al­leged­ly in­flat­ed Medicare re­im­burse­ments for Eylea

Ayisha Sharma

News Reporter

Re­gen­eron Phar­ma­ceu­ti­cals has been ac­cused of ma­nip­u­lat­ing Medicare re­im­burse­ment for its eye drug Eylea. If found li­able, the com­pa­ny could end up pay­ing three times …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times